Patient access scheme prompts NICE U-turn on Novartis' Tasigna, while BMS will appeal against no for Sprycel
This article was originally published in Scrip
Executive Summary
A patient access scheme has prompted NICE, the health technology appraisal institute for England and Wales, to change its mind and recommend Novartis's Tasigna (nilotinib) for chronic myeloid leukaemia (CML) patients unable to benefit from Glivec (imatinib), while Bristol-Myers Squibb is to appeal against negative recommendations on Sprycel (dasatinib). The institute also said no to Novartis' high-dose Glivec, partly because of a price increase.